Condition: Gastric Adenocarcinoma · Gastroesophageal Junction Adenocarcinoma · Sponsor: European Institute of Oncology
The primary objective is to validate, throughout a national real-world study, the efficacy and safety of Zolbetuximab combined with FOLFOX or XELOX regimens. Specific clinical issues will be studied by pre-planned subgroup analyses, addressing practical clinical needs which have not been specifically investigated in randomized clinical trials.
This description comes directly from the study's public registry record.
Chiara Alessandra Cella, MD · 00390257489258 · divisione.gastrointestinale@ieo.it
Lorenzo Gervaso, MD · 00390257489258 · divisione.gastrointestinale@ieo.it
Always discuss trial participation with your own doctor first.
| European Institute of Oncology | Milan, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07427992